Based on these findings, an ongoing phase 1 study is being conducted to evaluate the safety and tolerability of treatment with Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer, and only Wnt5a-negative or Wnt5a-low patients are enrolled in the study [178]. Here, WNT5A is linked to Familial prostate cancer.